Literature DB >> 6264131

Phosphorylation of acyclovir [9-(2-hydroxyethoxymethyl)guanine] in Epstein-Barr virus-infected lymphoblastoid cell lines.

B M Colby, P A Furman, J E Shaw, G B Elion, J S Pagano.   

Abstract

The extent of phosphorylation of 9-(2-hydroxyethoxymethyl)guanine (acyclovir [ACV]) in fresh peripheral leukocytes, in Epstein-Barr virus (EBV)-infected lymphoblastoid cell lines, and in herpes simplex virus type 1-infected lymphoblastoid (P3HR-1) and monkey kidney (Vero) cells was determined by high-pressure liquid chromatography, Mono-, di-, and triphosphorylated derivatives of [8-14C]ACV were detected at low levels at various times after superinfection of Raji cells with EBV. The extent of phosphorylation appeared to be related to the concentration of ACV in the medium. Small amounts of ACV mono-, di-, and triphosphates were formed in fresh peripheral leukocyte preparations from EBV- seropositive and -seronegative donors. Comparable ACV monophosphate levels were detected in EBV-negative BJAB and the EBV-positive BJAB/GC cell lines; however, no di- or triphosphate derivatives were detected. Comparable ACV-monophosphate levels were detected in both P3HR-1 and HSV-infected P3HR-1 cell lines; however, larger amounts of ACV di- and triphosphorylated derivatives were detected in the HSV-infected P3HR-1 cells. ACV was converted to the triphosphate to a greater extent in HSV-infected Vero cells than in mock-infected Vero cells or in HSV-infected P3HR-1 cells. ACV or its phosphorylated derivatives were converted to guanine nucleotides to a greater extent in lymphoblastoid cells than in fibroblasts (Vero). In conclusion, neither the productive replication of EBV nor the presence of latent viral DNA is required for ACV monophosphate formation in B lymphoblastoid cells. ACV triphosphate, however, was detected only in cells infected productively with EBV.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6264131      PMCID: PMC171191     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  19 in total

1.  A STUDY OF MALIGNANT TUMOURS IN NIGERIA BY SHORT-TERM TISSUE CULTURE.

Authors:  J V PULVERTAFT
Journal:  J Clin Pathol       Date:  1965-05       Impact factor: 3.411

2.  Production by EBV infection of an EBNA-positive subline from an EBNA-negative human lymphoma cell line without detectable EBV DNA.

Authors:  G B Clements; G Klein; S Povey
Journal:  Int J Cancer       Date:  1975-07-15       Impact factor: 7.396

3.  Inhibition of productive replication of Epstein-Barr virus DNA by phosphonoacetic acid.

Authors:  Y Yajima; A Tanaka; M Nonoyama
Journal:  Virology       Date:  1976-05       Impact factor: 3.616

4.  Epstein-Barr virus DNA synthesized in superinfected Raji cells.

Authors:  J E Shaw; T Seebeck; J L Li; J S Pagano
Journal:  Virology       Date:  1977-04       Impact factor: 3.616

5.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

6.  Epstein-Barr virus-associated thymidine kinase.

Authors:  S T Chen; J E Estes; E S Huang; J S Pagano
Journal:  J Virol       Date:  1978-04       Impact factor: 5.103

7.  Replication of viral deoxyribonucleic acid and breakdown of cellular deoxyribonucleic acid in Epstein-Barr virus infection.

Authors:  M Nonoyama; J S Pagano
Journal:  J Virol       Date:  1972-04       Impact factor: 5.103

8.  Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji).

Authors:  M A Epstein; B G Achong; Y M Barr; B Zajac; G Henle; W Henle
Journal:  J Natl Cancer Inst       Date:  1966-10       Impact factor: 13.506

9.  Persistent herpes simplex virus infections established in two Burkitt lymphoma derived cell lines.

Authors:  W G Robey; B J Graham; C L Harris; M J Madden; G R Pearson; G F Vande Woude
Journal:  J Gen Virol       Date:  1976-07       Impact factor: 3.891

10.  Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas.

Authors:  G Klein; T Lindahl; M Jondal; W Leibold; J Menézes; K Nilsson; C Sundström
Journal:  Proc Natl Acad Sci U S A       Date:  1974-08       Impact factor: 11.205

View more
  14 in total

1.  Characterization of the Epstein-Barr virus-encoded thymidine kinase expressed in heterologous eucaryotic and procaryotic systems.

Authors:  E Littler; J R Arrand
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

2.  Comparative efficacy and selectivity of some nucleoside analogs against Epstein-Barr virus.

Authors:  J C Lin; M C Smith; J S Pagano
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

3.  Epstein-Barr virus transformation of human B lymphocytes despite inhibition of viral polymerase.

Authors:  J W Sixbey; J S Pagano
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

4.  The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase.

Authors:  E A Gustafson; A C Chillemi; D R Sage; J D Fingeroth
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

5.  Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus.

Authors:  J C Lin; M C Smith; J S Pagano
Journal:  J Virol       Date:  1984-04       Impact factor: 5.103

6.  Effect of arabinofuranosylthymine on the replication of Epstein-Barr virus and relationship with a new induced thymidine kinase activity.

Authors:  T Ooka; A Calender; M de Turenne; J Daillie
Journal:  J Virol       Date:  1983-04       Impact factor: 5.103

7.  Location and characterization of the bovine herpesvirus type 4 thymidine kinase gene; comparison with thymidine kinase genes of other herpesviruses.

Authors:  P Lomonte; M Bublot; P P Pastoret; E Thiry
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

8.  Metabolism of acyclovir in virus-infected and uninfected cells.

Authors:  P A Furman; P de Miranda; M H St Clair; G B Elion
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

9.  Crystal structure of poxvirus thymidylate kinase: an unexpected dimerization has implications for antiviral therapy.

Authors:  Christophe Caillat; Dimitri Topalis; Luigi A Agrofoglio; Sylvie Pochet; Jan Balzarini; Dominique Deville-Bonne; Philippe Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-29       Impact factor: 11.205

10.  Phosphorylation of acyclovir in vitro in activated Burkitt somatic cell hybrids.

Authors:  A K Datta; J S Pagano
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.